Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions ranging from liver
steatosis (NAFL), steatohepatitis (NASH), advanced liver fibrosis and ultimately leads to
cirrhosis in a significant proportion of individuals. NAFLD is intimately associated with
insulin resistance and associated disorders, such as type 2 diabetes, metabolic syndrome and
dyslipidemia.
Bempedoic acid, an ATP-citrate lyase inhibitor, is recently approved for patients with
dyslipidemia as a second line drug. Bempedoic acid reduces liver fat in mice model of NASH.
Data regarding the effect of bempedoic acid on human liver fat are scarce. Therefore, the
current study is planned to evaluate the effect of bempedoic acid versus standard treatment
on liver and pancreatic fat content in patients with NAFLD